Skip to content
Bored Studies
RecruitingPhase 4

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Eidos Therapeutics, a BridgeBio company · NCT07695701

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–80 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
150
US sites recruiting
1
Study start
July 2026
Record last updated
July 29, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Being studied: Acoramidis (AG10) oral tablet

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Participants aged 18 to 80
  • Confirmed diagnosis of ATTR-CM requiring targeted therapy
  • At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >35%; left ventricular (LV) wall thickness ≥12 mm.
  • Heart failure condition has been clinically stable for at least 6 weeks prior to screening.

Key Exclusion Criteria

  • Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator).
  • Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening.
  • Hemodynamic instability.
  • Likely to undergo heart transplantation within 12 months from screening.
  • Confirmed diagnosis of AL amyloidosis at screening.
  • At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3.
  • Prior or current treatment with acoramidis.

Recruiting US locations

Study contacts (from the official record)

  • Medical Information · 1-844-550-2246 · medinfo@bridgebio.com
All heart & blood pressure studies in Missouri →
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis (NCT07695701) | Bored Studies